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Abstract 
Background: Interleukin 17 (IL-17) is a proinflammatory cytokine produced by a new subset of activated CD4+ T 
cells, Th17 cells. We previously showed that increased Th17 cell populations were presented in human medulloblas-
toma-infiltrating T cells and peripheral blood. In this study, we attempted to address the possible role of Th17 cells in 
the biologic activity of IL-17 for tumor control.
Methods: We grafted fresh surgically obtained medulloblastoma into syngeneic athymic nude/nude mice. We 
intrapertonially injected splenocyte and murine IL-17 in mice on the second day. The tumor volume and the life spans 
of the mice were measured. Meanwhile, the IL-17, IL-6, IL-23, Ccl2, Ccl20 and IFN-gamma expression in the tumors was 
also examined by real-time PCR, Western blot and enzyme-linked immunosorbent assay.
Results: We found that medulloblastoma growth in IL-17-injected mice was significantly inhibited compared to the 
non-IL-17 treated mice. In contrast to the IL-17 antitumor activity observed in mice injected with splenocytes, we 
observed that IFN-gamma, IL-6, IL-23, Ccl2, and Ccl20 proteins were significantly increased in tumor tissues of mice 
injected with IL-17.
Conclusions: These experiments suggest that IL-17 may promote splenocyte antitumor activity in medulloblastoma. 
We postulate that IL-17’s antitumor activity may be related to the increased protein levels of IFN-gamma, IL-6, IL-23, 
Ccl2, and Ccl20.
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Background
Medulloblastoma is a malignant tumor of the cerebellum 
and one of the most frequent malignant tumors in chil-
dren. Medulloblastoma is usually associated with a worse 
prognosis than other pediatric tumors. Moreover, it is 
the most common malignant pediatric brain tumor. The 
median age of children at diagnosis is 5-year old, and the 
tumor age range extends into young adulthood. Current 
therapies have serious adverse effects such as postopera-
tive mutism, neurocognitive deficits, endocrinopathies, 
and sterility [1–7]. There is compelling evidence showing 
the immune system’s vital role regarding diverse malig-
nant tumors, as it will affect cancer cell proliferation, 
migration, and survival [4, 8, 9].
Th17 cells are a new member of the CD4+ effector T 
cell family and characterized as preferential produc-
ers of IL-17A, IL-17F, IL-21, and IL-22. Retinoid orphan 
nuclear receptor (RORC), which encodes the ortholog 
RORyt, is a key regulator in Th17 cell differentiation. 
IL-23 and IL-6 also play a role in human Th17 cells 
in vitro. Th17 cell differentiation is also less well under-
stood in vivo and in vitro. Th17 cells play a physiological 
role in promoting host defense against infectious agents 
and sometimes contribute to autoimmune disease [10, 
11]. Recently, accumulated evidence showed that Th17 
cells and interleukin-17 have increased frequencies 
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and ovarian cancer. However, the role of Th17 and IL-17 
in tumor development has been controversial. Th17 and 
IL-17 have beneficial, detrimental, direct, and indirect 
effects on some tumors’ development. Th17’s role in 
tumors is dependent on the tumor’s classification and 
microenvironment. Many tumor cell types also bear 
IL-17 receptor alpha (IL-17RA), the specific receptor for 
IL-17 [12–15].
The accumulated evidence demonstrated that IL-17 
may have a direct impact on the tumor cells’ biological 
behavior in the local microenvironment. Some settings 
demonstrated that IL-17 and Th17 had an inverse corre-
lation with certain cancer’s progression in clinical stud-
ies. Much evidence showed that IL-17 increased vascular 
endothelium and tumor neoangiogenesis and promoted 
tumor cell development in mice [14, 15]. However, other 
settings demonstrated that IL-17 induced tumor suppres-
sion and even eradication by facilitating the immune cell 
recruitment in  vivo [16, 17]. Our previous studies have 
shown increased IL-17+ T cell numbers within medul-
loblastoma tumors [18]. However, the direct effects and 
underlying mechanisms of IL-17 in medulloblastoma cell 
growth remains elusive. Thus, in this study, we attempted 
to do a tentative exploration in the role of IL-17 on 
medulloblastoma in nude mice with splenocyte injec-
tion. We also investigated the expressions of IL-17-re-




We obtained 6- to 8-week-old female wild-type Balb/c 
mice and Balb/c athymic nude/nude mice from the Labo-
ratory Animal Center of Fudan University. Mice were 
maintained under pathogen-free conditions in this study. 
This study was approved by the Huashan Institutional 
Review Board, Fudan University, Shanghai, China.
Patients and tumor cells
According to the previous study [19], we collected tumor 
tissues during operation. No patient received radio-
therapy or chemotherapy preoperatively. This study was 
approved by the Ethical Committee of Fudan University, 
and we obtained written informed consent from all indi-
viduals involved in this research.
We cultured tumor cells in high-glucose Dulbec-
co’s modified Eagle medium (DMEM) supplemented 
with 10  % heat-inactivated fetal bovine serum (FBS), 
2  mM  l-glutamine, 100 units/mL penicillin, 100  μg/mL 
streptomycin, and 0.01 % mercaptoethanol. All cells were 
maintained at 37  °C in a humidified incubator in 5  % 
CO2. The cells were then collected and resuspended at 
1 ×  106/100 μL in PBS, and we then injected a 100-μL 
suspension into mice shoulders.
Splenocyte preparation and proliferation
According to the previous study [20], splenocytes 
(2 × 107/mL) were purified and stimulated with 2 μg/mL 
ConA in complete DMEM [DMEM with 10 % fetal calf 
serum (FCS), 10 μM HEPES, 50 μM β-mercaptoethanol, 
2  mM  l-glutamine, and 50  IU/mL penicillin–strepto-
mycin] in 25-mL flasks for 72  h. Splenocytes were then 
washed three times with PBS (pH 7.4). Freshly isolated 
splenocytes (2 × 107 per well) were cultured in a flat-bot-
tomed plate in triplicate in complete DMEM with ConA 
(2 μg/mL) at 37 °C in 5 % CO2 for 72 h.
Mice grouping
Thirty animals were randomly divided into the saline-
injected group (n  =  10), splenocyte-injected group 
(n  =  10), and splenocyte-IL-17-injected group. Medul-
loblastoma challenge time was used as the baseline 
(time point 0). In the splenocytes-injected group, the 
mice were intraperitoneally injected with 5  ×  107 allo-
genic splenocytes in 2  mL sodium butyrate solu-
tion 48  h after medulloblastoma challenge. While in 
the splenocyte-IL-17-injected group, 5  ×  107 allo-
genic splenocytes and IL-17 (ProSpec) (80  ng/mL) in 
2  mL sodium butyrate solution were intraperitoneally 
injected at the same time. The injected doses were rec-
ommended by other authors and were approved by our 
pilot experiment [20, 21]. The mice in the saline-injected 
group were injected intraperitoneally with the same vol-
ume of normal saline.
Then, four mice in each group were randomly eutha-
nized for tumor sampling  at 28 days. Tumors from the 
euthanized mice in each group were used to examine 
IL-6, IL-23, Ccl2, and Ccl20 protein expressions by West-
ern blotting and real-time PCR. The remaining six mice 
per group were observed for survival duration.
Tumor growth inhibition assay in mice
After four mice in each group were randomly eutha-
nized, we observed the remaining six mice per group for 
survival duration after medulloblastoma challenge. We 
measured tumor diameter (in millimeters) twice every 
week and determined tumor volume according to the fol-
lowing formula: volume = (a × b)2/2 (a long diameter; b 
short diameter).
Survival analysis
The remaining six mice in each group were used to meas-
ure life span. We analyzed survival curves using the non-
parametric Kaplan–Meier method.
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Western blotting
To determine the expressions of inflammatory factors 
and cytokines, we analyzed the fresh tissue samples of 
these medulloblastoma xenografts by Western blotting. 
Cell lysates were isolated in a protein extraction buffer 
containing 150  mM NaCl, 20  mM Tris (pH 7.5), 5  mM 
EDTA, 0.1  % Triton X-100, 5  % glycerol, and 2  % SDS. 
After incubating at 4  °C for 30  min, the protein con-
centrations were centrifuged at 12,000  rpm for 30  min. 
Protein concentrations were determined using Bradford 
assay. Proteins were then denatured in a sample buffer 
containing 2-mercaptoethanol and bromophenol blue for 
10 min at 95 °C. Equal protein amounts were resolved by 
SDS-PAGE and then transferred to PVDF membranes. 
The membranes were blocked in 5  % skimmed milk in 
tris-buffered saline containing 0.1  % Tween 20 (TBST) 
and were then incubated overnight at 4  °C with the pri-
mary antibodies (Santa Cruz Biotechnology, Inc). After 
being washed with PBS three times, the membranes were 
incubated in secondary antibody at room temperature. 
We detected protein band intensity using an enhanced 
chemiluminescence detection system.
Real‑time RT‑PCR
We dissected medulloblastoma xenograft samples and 
extracted mRNA using UNIzol reagent treated with RNase-
free DNase I (Takara, Japan). Reverse transcription was per-
formed with Omniscript reverse transcriptase (QIAGEN). 
The 20-μL reactions contained: DNase-treated RNA, 1 μM 
random hexamer primer, deoxynucleoside triphosphate 
mix, 1 U of RNase inhibitor (Ambion), and Omniscript 
reverse transcriptase. Incubation conditions were those 
suggested by the manufacturer: 37 °C for 1 h and 93 °C for 
5  min. We performed real-time PCR analysis with SYBR 
Green I (Takara, Japan). The 50-μL reactions contained: 
cDNA; 0.5  μM of primers specific for primer sequences: 
Il-6 forward, 5′-TGATGGATGCTACCAAACTGG-3′ and 
reverse, 5′-TTGGTCCTTAGCCACTCCTTC-3′ (2.5  mM 
MgCl2); Il23a forward, 5′-AATGCTATGGCTGTTGCC 
CTG-3′ and reverse, 5′-CGGATCCTTTGCAAGCAG 
AAC-3′(3.5  mM MgCl2); Ccl2 forward, 5′-TGATCC 
CAATGAGTAGGCTGG-3′ and reverse, 5′-TGCTTGA 
GGTGGTTGTGGAA-3′ (2.5  mM MgCl2); Ccl20 for-
ward, 5′-TCTTCCTTGCTTTGGCATGG-3′ and reverse, 
5′-TCTGCTTTGGATCAGCGCA-3′ (2.5  mM MgCl2); 
GAPDH forward, 5′-ACCACAGTCCATGCCATCAC-3′ 
and reverse, 5′- TCCACCACCCTGTTGCTGTA-3′ (2.5   
mM MgCl2). PCR was performed in ABI PRISM 7900HI 
(Applied Biosystems), and cycle conditions were 50  °C for 
2 min and 95 °C for 10 min, followed by 40 cycles of 95 °C 
for 15 s and 60 °C for 1 min. Endogenous control (GAPDH) 
was used for each sample in the same plate. Gene expression 
was quantified by the 2−ΔΔCt method.
Enzyme‑linked immunosorbent assay (ELISA)
Sera and ascitic fluid were collected from three groups of 
mice on day 14. The serum and ascitic fluid samples were 
tested for the productions of IL-17 and IFN-gamma using 
ELISA kits, according to the manufacturer’s instructions 
(Quantikine).
Statistical analysis
We performed statistical analysis using SPSS 16.0 for 
Windows software. The reported values were expressed 
as means ±  standard deviations. Statistical analysis was 
performed using Student’s t test and χ2 test, and we 
analyzed the survival curves using the non-parametric 
Kaplan–Meier method. Differences were judged as sig-
nificant at a value of P < 0.05.
Results
IL‑17 enhanced splenocyte injections’ inhibition 
on medulloblastoma growth in vivo
As shown in our previous work, the Th17 population 
was increased significantly both in peripheral blood and 
tumor-infiltrating T cells of medulloblastoma patients. 
To investigate the role of Th17 in medulloblastoma devel-
opment in  vivo, we challenged Balb/c nu/nu mice with 
medulloblastoma injected into the right shoulder subcu-
taneously. Then, we injected the mice with allogenic sple-
nocytes intraperitoneally 2  days after medulloblastoma 
challenge. We added IL-17 (80 ng/mL) to the splenocyte 
suspension after injection in the test group but not in the 
control group.
On day 28 after medulloblastoma challenge, mice injected 
with IL-17 exhibited significantly smaller tumor sizes com-
pared to the non-IL-17 treated mice (1966.81 ± 378.16 mm3 
in IL-17-treated group vs 4468.18 ± 923.64 mm3 in the non-
IL-17-treated group; P  <  0.01). The tumor growth curves 
illustrated that the medulloblastoma cells grew slowly in the 
IL-17-treated group on days 14, 21, and 28 after medullo-
blastoma challenge (Fig. 1).
Meanwhile, on day 28 after the challenge, the mean 
medulloblastoma volumes in the Balb/c nu/nu mice 
without splenocyte injection exhibited bigger tumor sizes 
compared to the mice in both groups with splenocyte 
injection. The medulloblastoma growth curves showed 
that the mean tumor size in the splenocyte-injected mice 
was bigger than the mice (with or without IL-17) injected 
with splenocytes on days 14, 21, and 28 after tumor 
challenge, as shown in Fig.  1. However, the difference 
was significant between the non-splenocyte-injected 
group and the splenocyte-injected group without IL-17 
(6012.45 ±  572.95 vs 4468.18 ±  923.64  mm3; P  <  0.01, 
Fig. 1).
To investigate the effect of IL-17 alone in tumor 
growth in Balb/c nu/nu mice, we injected the same dose 
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of IL-17 (80 ng/mL) in Balb/c nu/nu mice without sple-
nocyte injection. There was no tumor size difference 
in the Balb/c nu/nu mice without splenocyte injection 
between the IL-17-treated group and non-IL-17-treated 
group on days 14, 21, and 28 (data not shown). There-
fore, IL-17’s effect on medulloblastoma inhibition is 
splenocyte dependent in Balb/c nu/nu mice. This sug-
gested that IL-17 may enhance the splenocyte injections’ 
inhibition of medulloblastoma growth in  vivo in nude 
mice, and IL-17 alone may have no significant effect on 
medulloblastoma.
Splenocyte injection prolonged nude mice life spans
The remaining six mice in each group were used to meas-
ure life span. Survival curves were analyzed using the non-
parametric Kaplan–Meier method. As shown in Fig.  2, 
the tumor survival curves illustrated that the splenocyte-
injected group lived longer than those in the non-spleno-
cyte-injected group (P  <  0.05). Additionally, between the 
two splenocyte-injected groups, the IL-17-treated group 
had an increased survival time compared to the non-IL-17-
treated group, and the difference was significant in statis-
tics by the Kaplan–Meier method (P < 0.01). It suggested 
that IL-17 may enhance the therapeutic effects of spleno-
cyte injection against medulloblastoma in nude mice.
IL‑6 and IL‑23 were overexpressed in IL‑17‑treated mice
Because IL-6 and IL-23 are cytokines closely related to 
IL-17, we also examined the expression levels of IL-6 and 
IL-23 in the medulloblastoma xenografts by real-time 
PCR and Western blot to investigate the microenviron-
ment changes induced by IL-17. The medulloblastoma 
xenografts were removed from euthanized mice of all 
groups on day 28, and cell lysates were isolated for pro-
tein and mRNA extraction. As shown in Fig. 3, the West-
ern blot results were in accordance with that of real-time 
PCR. Compared to the non-splenocyte-injected group, 
results obtained from splenocyte-injected mice showed 
that IL-6 and IL-23 were overexpressed in tumors. More-
over, the results also revealed that the in the splenocyte-
injected group, the IL-6 and IL-23 expression levels were 
significantly higher in the IL-17-treated group than the 
non-IL-17-treated group. These results implicated that 
splenocyte injection may promote the expressions of 
IL-6 and IL-23 in medulloblastoma xenografts in nude 
mice, and IL-17 may enhance the effects of splenocyte 
injection.
IL‑17 enhanced the antitumor effect of splenocyte 
injection on Ccl2 and Ccl20
Because Ccl2 and Ccl20 are critical inflammatory media-
tors, their expressions were also determined by real-time 
PCR and Western blot methods on day 28 to investi-
gate additional mechanisms involved in the anti-tumor 
immunity of IL-17. The results of both real-time PCR 
and Western blot indicated that the expression levels of 
Ccl2 and Ccl20 were elevated in the splenocyte-injected 
group compared to the non-splenocyte-injected group. 
Moreover, the expression levels of Ccl2 and Ccl20 were 
higher in the splenocyte-injected group with IL-17 than 
that without IL-17 (Fig. 4). These results implicated IL-17 
may enhance the antitumor effect of splenocyte injection 
on inflammatory mediators Ccl2 and Ccl20.
IL‑17 was active in IL‑17‑treated mice
We measured the levels of IL-17 in the serum and 
ascitic fluid samples by ELISA and in the tumor sam-
ples by Western blot on day 14 to determine where the 
cytokine is present and active. As shown in Fig.  5a, the 
Fig. 1 Tumor growth curve. The medulloblastoma tumor growth 
rate was decreased in the mice injected with splenocytes with IL-17. 
The mean tumor volume on day 28 in the splenocyte-injected 
group with IL-17 was smaller than in the splenocyte-injected group 
without IL-17 (1966.81 ± 378.16 mm3 in IL-17-treated group vs 
4468.18 ± 923.64 mm3 in non-IL-17-treated group; P < 0.01). Mean-
while, the mean tumor volume in non-splenocyte-injected mice was 
the largest (6012.45 ± 572.95 mm3)
Fig. 2 IL-17 increased survival time of mice injected with spleno-
cytes. The splenocyte-injected group lived longer than those in the 
non-splenocyte-injected group (P < 0.05). Moreover, in splenocyte-
injected mice, the IL-17-treated group had a significantly increased 
survival time compared to the non-IL-17-treated group (P < 0.01)
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ELISA results obtained from splenocyte-injected group 
with IL-17 showed that IL-17 levels were higher in the 
serum and ascitic fluid samples than those without IL-17 
(208.54 ± 8.87 vs 152.97 ± 7.01 pg/mL in serum, P < 0.01; 
34.39  ±  6.09 vs 20.89  ±  3.20  pg/mL in ascitic fluid; 
P  <  0.01). Meanwhile, in the non-splenocyte-injected 
Fig. 3 a The medulloblastoma xenografts were removed from euthanized mice of all groups on day 28, and cell lysates were isolated for protein 
and mRNA extraction. Total RNA was extracted, and the mRNA levels of IL-6 and IL-23 were analyzed using real-time PCR. Endogenously expressed 
GAPDH amplification in the same samples was used for a loading control. The experiment was performed three times with consistent results. p 
values were calculated with the t test; *p < 0.05; **p < 0.01. b Cell lysates were isolated in a protein extraction, and Ccl2 and Ccl20 protein was 
analyzed using Western blot. The similar expressions of Ccl2 and Ccl20 proteins in medulloblastoma cells were confirmed by Western blot assay and 
densitometry assessment. p values were calculated with the t test; *p < 0.05; **p < 0.01
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group, the IL-17 levels both in serum (58.38 ± 24.65 pg/
mL) and ascitic fluid (12.49  ±  4.02  pg/mL) were the 
lowest. Whereas, the Western blot results revealed that 
IL-17 levels were not increased in tumor samples in 
the IL-17-treated group compared with the non-IL-17-
treated group (Fig.  5b). These results implicated that 
IL-17 may influence tumor-suppressing activity of the 
splenocytes rather than act directly in the tumors.
Fig. 4 a The medulloblastoma xenografts were removed from euthanized mice of all groups on day 28, and cell lysates were isolated for protein 
and mRNA extraction. Total RNA was extracted, and the mRNA levels of Ccl2 and Ccl20 was analyzed using real-time PCR. Endogenously expressed 
GAPDH amplification in the same samples was used for a loading control. The experiment was performed three times with consistent results. p 
values were calculated with the t test; *p < 0.05; **p < 0.01. b Cell lysates were isolated in a protein extraction, and Ccl2 and Ccl20 proteins were 
analyzed using Western blot. The similar expressions of Ccl2 and Ccl20 proteins in medulloblastoma cells were confirmed by Western blot assay and 
densitometry assessment. p values were calculated with the t test; *p < 0.05; **p < 0.01
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IL‑17 enhanced the effect of splenocyte injection 
on IFN‑gamma
We also assess whether IFN-gamma is expressed by IL-17 
stimulated splenocytes that potentially influence the tumor. 
The levels of IFN-gamma in the serum and tumor samples 
were determined respectively by ELISA and Western blot 
on day 14. As shown in Fig. 6a, the ELISA results indicated 
that the levels of IFN-gamma in serum were elevated in the 
splenocyte-injected group compared with the non-spleno-
cyte-injected group (261.60 ± 5.73 vs 191.85 ± 22.54 pg/
mL, P < 0.01), and it was higher in the splenocyte-injected 
group with IL-17 than that without IL-17 (306.88 ± 10.35 
vs 261.60 ± 5.73 pg/mL; P < 0.01). The Western blot results 
showed that the levels of IFN-gamma in tumor samples 
Fig. 5 a Mean ± SD IL-17 concentrations using enzyme-linked immunosorbent assay demonstrated a statistically significant increase in the levels 
of IL-17 in serum and ascitic fluid samples in the mice of splenocyte-injected group with IL-17 than that without IL-17. p values were calculated 
with the t test; *p < 0.05; **p < 0.01. b The medulloblastoma xenografts were removed from mice of all groups on day 14. Cell lysates were isolated 
in a protein extraction, and IL-17 protein was analyzed using Western blot and densitometry assessment. p values were calculated with the t test; 
*p < 0.05; **p < 0.01
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were in accordance with that in serum (Fig.  6b). These 
results implicated IL-17 may enhance the anti-tumor effect 
of splenocyte injection on IFN-gamma.
Discussion
Medulloblastoma is a high-grade malignant brain tumor 
with a dismal prognosis, and its current therapeutic 
treatments are often associated with severe side effects 
[1–3]. Recent tumor immunology field advances may 
offer better ways to treat patients with medulloblastoma 
and reduce the side effects. Th17 cells, found recently, 
are a new subtype of the CD4+ effector T cell family and 
characterized as preferential producers of IL-17, IL-21, 
and IL-22. IL-23 and IL-6 have been shown to play a 
role in human Th17 cells in vitro [10, 11]. Several stud-
ies showed elevated IL-17 and Th17 cells in some types 
of tumors, such as in ovarian cancer [12, 13]. However, 
precisely how this might contribute to tumor growth or 
suppression remains unclear.
Muranski et al. [16] reported that tumor-specific Th17 
cells can erase established melanoma in mice. Martin-
Orozco et  al. [17] also reported that IL-17 and tumor-
specific Th17 cells had protective role in antitumor 
responses by promoting tumor-specific cytotoxic T cell 
responses. The identification of Th1 cells has facilitated 
the development of various T cell-based tumor therapies 
because of its capability of promoting tumor rejection. 
However, a recent study demonstrated that Th17 may be 
more effective in promoting tumor rejection than Th1 
cells [16]. These findings suggest that Th17 cells may also 
play an important role in tumor pathogenesis.
Although Th17 cells have been investigated in several 
types of human tumors, their biological function in tumor 
development remains elusive. In our previous study, 
we measured the prevalence of Th17 cells in peripheral 
blood and tumor-infiltrating lymphocytes and found that 
increased populations of Th17 cells were present both 
in medulloblastoma-infiltrating T cells and in patients’ 
peripheral blood. In addition, the mRNA levels of IL-17, 
IL-23 and RORC in tumor tissues and the serum con-
centrations of IL-17 and IL-23 protein were increased 
in patients with medulloblastoma [18]. Cytokines play 
an important role in regulating tumor progression and 
metastasis, and IL-17 is one of the most important Th17 
cytokines [10, 11]. Several studies showed that IL-17 
has a potent antitumor activity that appears to be T-cell 
dependent [17, 22]. In contrast, IL-17’s role in promoting 
tumor growth has also been reported. The tumor-promot-
ing roles of IL-17 may be mediated by angiogenesis [23].
In this study, we used an athymic nude mice model to 
establish medulloblastoma. We found that, when sple-
nocytes were injected into nude mice, medulloblastoma 
growth rates decreased compared with the non-spleno-
cyte-injected nude mice. We also found that the medul-
loblastoma growth rate could be further inhibited in 
splenocyte-injected mice with IL-17. The results showed 
that splenocyte injection might inhibit medulloblastoma 
growth in nude mice. The results also showed that the 
anti-tumor effects of splenocytes might be enhanced by 
IL-17.
Fig. 6 a Mean ± SD IFN-gamma concentrations using enzyme-
linked immunosorbent assay demonstrated a statistically significant 
increase in the levels of IFN-gamma in serum samples in the mice of 
splenocyte-injected group with IL-17 than that without IL-17. p values 
were calculated with the t test; *p < 0.05; **p < 0.01. b The medul-
loblastoma xenografts were removed from mice of all groups on day 
14. Cell lysates were isolated in a protein extraction, and IFN-gamma 
protein was analyzed using Western blot and densitometry assess-
ment. p values were calculated with the t test; *p < 0.05; **p < 0.01
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We also found that IL-17 levels were higher in serum, 
ascitic fluid samples in the IL-17-treated group than the 
non-IL-17-treated group. However, IL-17 levels were 
not increased significantly in tumor tissue samples in 
the IL-17-treated group. So IL-17 may influence tumor-
suppressing activity of the splenocytes rather than act 
directly in the tumors.
IL-17 is well known for being capable of inducing the 
secretion of many inflammatory mediators in diverse 
cell types, including stromal cells and tumor cells [24, 
25]. Moreover, cytokines’ roles are highly tumor-type 
dependent and cell-microenvironment dependent [25]. 
Th17-related cytokines such as IL-6 and IL-23 are closely 
related to IL-17. IL-6 and IL-23 have been found in vari-
ous tumors, including prostate and ovarian tumors as well 
as colorectal cancers and other malignancies [12–15, 26].
IL-6 was found to increase the proliferation of human 
tumors transplanted into nude mice and immunocompe-
tent mice [27]. However, IL-6 was also found to inhibit 
immunogenic tumor growth by stimulating antitumor 
T-cell activity. IL-6 activates the JAK-STAT3 pathway, 
leading to increased tumor-infiltrating lymphocytes, 
which has been widely documented [28]. IL-17 was sug-
gested to activate IL-6 production through activating 
the AKT signaling pathway. Then, IL-6 promoted signal 
transducer and activation of transcription 3 (STAT3) 
signaling and in turn increased IL-8 and VEGF. Support-
ing these findings, IL-17 promoted STAT3 phosphoryla-
tion and lymphocyte infiltration [29, 30].
IL-23 is an important cytokine in Th17 cell regulation. 
In contrast to our data, IL-23 has been shown to promote 
tumor progression and prevent anti-tumor immunity [31]. 
IL-23 produced by macrophages promotes tumor growth 
by activating STAT-3 in the macrophages and Treg cells 
[32]. Meanwhile, IL-23 may have a distinct function in 
cancer immunity by regulating other cells or factors. It is 
also possible that IL-23 may have different immune func-
tions in different inflammatory settings. IL-23 may pro-
vide a supportive role for certain types of tumor chronic 
inflammation, whereas it might play a role in inhibiting 
several tumors’ progression in acute inflammation [33, 34].
Thus, in this study, we found that IL-17 up-regulated 
the expressions of IL-6 and IL-23 in splenocyte-injected 
nude mice. Moreover, when splenocytes were incubated 
with IL-17 and injected into athymic nude mice, the 
medulloblastoma growth rate was decreased compared 
with the non-IL-17-treated group. So, IL-6 and IL-23 
might provide protection to athymic nude mice against 
medulloblastomas in our current data. The results also 
suggest that IL-17 in mice might activate splenocytes 
and/or medulloblastoma cells to produce chemokines 
Ccl20 and Ccl2, which might promote splenocyte 
recruitment and anti-tumor activity. IL-17’s effects were 
thought to be operated through augmented recruitment 
and anti-tumor activity of splenocytes to medulloblas-
toma in mice.
IFN-gamma is a cytokine that plays important roles 
in preventing development of primary and transplanted 
tumors [35]. Th17 cells can promote the production of 
IFN-gamma by themselves other Th cells [36]. In this 
study, the results indicated that the levels of IFN-gamma 
were elevated in the splenocyte-injected group com-
pared with the non-splenocyte-injected group, and it was 
higher in the splenocyte-injected group with IL-17 than 
that without IL-17. Therefore, IFN-gamma might be up-
regulated by IL-17 stimulated splenocytes that poten-
tially influence the tumor.
Although splenocyte injection alone did provide some 
degree of tumor protection in our medulloblastoma 
model as well, the splenocyte injections with IL-17 were 
more effective in the medulloblastoma model in athymic 
mice. IL-17’s effects on tumors are influenced by the 
immune system, and it inhibits tumor progression in the 
presence of lymphocytes.
The anti-tumor activities of cytokines and chemokines, 
like with IL-17, which often depend on the tumor model 
and local microenvironment, must be taken into consid-
eration when these molecules are used in tumor immu-
notherapy. In the absence of lymphocytes, though, IL-17 
promoted tumor progression. This notion is consistent 
with our current study on nude mice bearing medul-
loblastomas with splenocyte injections. The protective 
function of Th17 cells against tumors is probably due to 
their ability to enhance inflammatory responses [17].
Punt et  al. reported that an increased number of 
IL-17(+) cells were significantly correlated with the 
absence of vaso-invasion, smaller tumor size and less 
infiltration depth in squamous cell carcinoma [37]. 
Author also reported that a high number of Th17 cells 
were an independent prognostic factor for improved sur-
vival in squamous cervical cancer [38]. Th17 cells are a 
subpopulation of IL-17(+) cells and had a different cor-
relation with prognosis than total IL-17 [39]. Although 
Th17 cells had some success in a variety of anti-tumor 
therapies, in the majority of reported cases it has resulted 
in limited antitumor responses [16, 17, 40]. We used 
IL-17 to mediate medulloblastoma rejection. The use of 
IL-17 is more convenient and secure than using Th17 
cells. IL-17 use does not require the culture and identi-
fication of specific Th17 cells. Moreover, IL-17 injections 
may cause fewer allergic reactions compared to T cell 
injections.
Conclusions
In conclusion, we found that splenocytes might inhibit 
the growth rates of medulloblastomas that were 
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transplanted into nude mice, and this inhibition might be 
enhanced by IL-17. Furthermore, our study showed that 
injecting IL-17 significantly increased the IFN-gamma, 
IL-6, IL-23, Ccl2, and Ccl20 chemokine productions in 
medulloblastoma xenografts in vivo. We speculated that 
IL-17 might promote IFN-gamma, IL-6, IL-23, CCL-20, 
and Ccl2 expressions in the subcutaneous medulloblas-
toma model.
Although our results indicate a probable role for 
IL-17 in the antitumor activity of splenocytes, we can-
not exclude the possibility that other effectors cooperate 
with splenocytes to inhibit medulloblastoma growth. To 
illuminate the functions of IL-17 and Th17 on the devel-
opment of medulloblastoma and other tumors, further 
research is essential.
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